Drug intelligence / Profile preview

TAY-R2

Development stage: Preclinical
Lead developer: Tay Therapeutics
Modality: Small Molecules

Overview

TAY-R2 is a small molecule therapeutic candidate being developed by Tay Therapeutics for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) and other genetic diseases. Currently in the IND-enabling phase of development, TAY-R2 is part of the company's internal pipeline focusing on addressing genetic mutations. While the specific molecular target has not been publicly disclosed, Tay Therapeutics specializes in translational readthrough technologies designed to treat diseases caused by nonsense mutations.

Beyond the preview

Go deeper on TAY-R2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAY-R2.

Explore the full profile